Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 5/20 | 0.34 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5083033 | 0.75 | KDM4E (0.33) | CDK1ADORA2AADORA1 | |
| SCHEMBL5080055 | 0.70 | CDK1 (0.35) | CDK1YTHDC1CCNE2CCNE1CDK2 | |
| SCHEMBL5083699 | 0.69 | CDK1 (0.41) | CDK1CCNE2CCNE1CDK2 | |
| SCHEMBL5083038 | 0.68 | CDK1 (0.41) | CDK1CCNE2CCNE1CDK2 | |
| SCHEMBL16105077 | 0.66 | CDK1 (0.35) | CDK1CCNE2CCNE1CDK2 | |
| SCHEMBL2557634 | 0.66 | CDK1 (0.35) | CDK1CCNE2CCNE1CDK2 | |
| SCHEMBL5080066 | 0.66 | CDK1 (0.37) | CDK1CCNE2CCNE1CDK2 | |
| SCHEMBL2556488 | 0.65 | PDE4A (0.38) | CDK1YTHDC1ADORA3ADORA2AADORA1 | |
| SCHEMBL2556773 | 0.63 | PDE4A (0.37) | CDK1ADORA3ADORA2AADORA1CCNE2 | |
| SCHEMBL14659054 | 0.63 | P2RY1 (0.31) | YTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | CDK1 704/4885YTHDC1 147/4885ADORA3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.